Generated by AI
Veracyte, Inc. is a precision diagnostics company that develops genomic tests to help clinicians answer critical questions in cancer and other diseases. Veracyte’s current portfolio includes laboratory-developed tests for thyroid, prostate, bladder, and breast cancer, as well as tests for lung disease and lung cancer-related decision support. The company also provides products and services such as Afirma, Decipher, Percepta, Envisia, Prosigna, Immunoscore, and nCounter analysis capabilities, supporting diagnosis, prognosis, and treatment selection across multiple care settings. Its work is centered on using genomic and clinical data to reduce diagnostic uncertainty and improve decision-making for physicians, pathologists, and patients. Headquartered in South San Francisco, California, Veracyte operates as a global diagnostics business with a focus on molecular testing, evidence generation, and clinical utility in oncology and related specialties.
Website6000 Shoreline Court
South San Francisco, CA, 94080
United States
The latest articles about VCYT.
Veracyte is a Hold: Decipher growth is slowing, with management planning a 40% lower annual increase; consensus expects 2027 EPS to fall 19.38%. Click for more on VCYT stock.
Why Veracyte Stock Is Back Under The Microscope Veracyte (VCYT) rattled investors after resetting near term expectations for its Decipher prostate cancer test, even as quarterly revenue growth remained solid and management trimmed 2026 guidance. The latest reset around Decipher came on top of a sharp swing in sentiment, with Veracyte’s share price down 51.69% over the past week and 48.84% over the last three months, while the 1-year total shareholder return has fallen 42.06% even though the...
Summary of Jul 30's posts. Generated by AI.
Summary of Nov 5's posts. Generated by AI.
Summary of Nov 7's posts. Generated by AI.
Summary of Nov 5's posts. Generated by AI.
Investors talking about VCYT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.